Cargando…

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiore, Marco, Alfieri, Aniello, Di Franco, Sveva, Pace, Maria Caterina, Simeon, Vittorio, Ingoglia, Giulia, Cortegiani, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400227/
https://www.ncbi.nlm.nih.gov/pubmed/32645986
http://dx.doi.org/10.3390/antibiotics9070388
_version_ 1783566314400382976
author Fiore, Marco
Alfieri, Aniello
Di Franco, Sveva
Pace, Maria Caterina
Simeon, Vittorio
Ingoglia, Giulia
Cortegiani, Andrea
author_facet Fiore, Marco
Alfieri, Aniello
Di Franco, Sveva
Pace, Maria Caterina
Simeon, Vittorio
Ingoglia, Giulia
Cortegiani, Andrea
author_sort Fiore, Marco
collection PubMed
description Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until 12 February 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies published in peer-reviewed journals and in the English language. The primary outcome was all-cause mortality (longest follow-up) evaluated in patients with the diagnosis of infection with at least one pathogen; secondary outcomes were clinical and microbiological improvement/cure. Thirteen studies were included in the qualitative synthesis: 7 RCTs and 6 retrospective studies All the six retrospective studies identified carbapenamase-producing Enterobacteriaceae (CRE) as the cause of infection and for this reason were included in the network meta-analysis (NMA); the quality of the studies, assessed using the New Castle-Ottawa Scale, was moderate-high. In all the six retrospective studies included in the NMA, CZA was used in large part for off-label indications (mostly blood stream infections: 80–100% of patients included). No difference in mortality rate was observed in patients undergoing CZA combination therapy compared to CZA monotherapy [n = 503 patients, direct evidence OR: 0.96, 95% CI: 0.65–1.41].
format Online
Article
Text
id pubmed-7400227
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74002272020-08-23 Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis Fiore, Marco Alfieri, Aniello Di Franco, Sveva Pace, Maria Caterina Simeon, Vittorio Ingoglia, Giulia Cortegiani, Andrea Antibiotics (Basel) Article Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until 12 February 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies published in peer-reviewed journals and in the English language. The primary outcome was all-cause mortality (longest follow-up) evaluated in patients with the diagnosis of infection with at least one pathogen; secondary outcomes were clinical and microbiological improvement/cure. Thirteen studies were included in the qualitative synthesis: 7 RCTs and 6 retrospective studies All the six retrospective studies identified carbapenamase-producing Enterobacteriaceae (CRE) as the cause of infection and for this reason were included in the network meta-analysis (NMA); the quality of the studies, assessed using the New Castle-Ottawa Scale, was moderate-high. In all the six retrospective studies included in the NMA, CZA was used in large part for off-label indications (mostly blood stream infections: 80–100% of patients included). No difference in mortality rate was observed in patients undergoing CZA combination therapy compared to CZA monotherapy [n = 503 patients, direct evidence OR: 0.96, 95% CI: 0.65–1.41]. MDPI 2020-07-07 /pmc/articles/PMC7400227/ /pubmed/32645986 http://dx.doi.org/10.3390/antibiotics9070388 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fiore, Marco
Alfieri, Aniello
Di Franco, Sveva
Pace, Maria Caterina
Simeon, Vittorio
Ingoglia, Giulia
Cortegiani, Andrea
Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title_full Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title_fullStr Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title_full_unstemmed Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title_short Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
title_sort ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400227/
https://www.ncbi.nlm.nih.gov/pubmed/32645986
http://dx.doi.org/10.3390/antibiotics9070388
work_keys_str_mv AT fioremarco ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT alfierianiello ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT difrancosveva ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT pacemariacaterina ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT simeonvittorio ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT ingogliagiulia ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis
AT cortegianiandrea ceftazidimeavibactamcombinationtherapycomparedtoceftazidimeavibactammonotherapyforthetreatmentofsevereinfectionsduetocarbapenemresistantpathogensasystematicreviewandnetworkmetaanalysis